Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Henderson Clinical Trials LLC

Neither a doctor nor a teaching hospital

Research payments

$2,084,237

394 payments

Through program year 2025, Henderson Clinical Trials LLC is reported as receiving $2,084,237 in research payments, across 394 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $1,268,409 315
2024 Research $706,066 69
2023 Research $109,762 10

Breakdown

Who paid Research payments · program years 2023–2025
  1. GlaxoSmithKline, LLC. $669,998 101 payments
  2. Sanofi US Services Inc. $413,268 57 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $407,659 62 payments
  4. Moderna TX, Inc. $371,517 31 payments
  5. Eli Lilly and Company $97,473 1 payment
  6. Regeneron Pharmaceuticals, Inc. $51,185 124 payments
  7. Pfizer Inc. $38,375 4 payments
  8. Chiesi USA, Inc. $34,762 14 payments
Studies the money was for Research payments · program years 2023–2025
  1. A Multicentre Randomized, Double-Blind, Placebo-Controlled, Dose-Findi $479,884 46 payments
  2. A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age $371,517 31 payments
  3. A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment $215,311 36 payments
  4. TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis $183,348 25 payments
  5. A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Eval $158,468 48 payments
  6. Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) $142,606 19 payments
  7. A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Effect of Amlitelimab on Vaccine Antibody Responses in Adult Participants With Moderate to Severe Atopic Dermatitis $137,132 17 payments
  8. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index Greater Than 27 KG M2 and Atherosclerotic Cardiovascular Disease and Or Chronic Kidney Disease $97,473 1 payment
  9. AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma $51,185 124 payments
  10. A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies $51,007 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record